OncoMed Pharmaceuticals - OMED Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New OncoMed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMED

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for OncoMed Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for OMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in OncoMed Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market Perform$8.00 ➝ $1.50High
9/21/2018HC WainwrightLower TargetNeutral$3.00 ➝ $2.00High
3/9/2018HC WainwrightReiterated RatingHold$3.00High
2/23/2018HC WainwrightReiterated RatingNeutralHigh
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
OncoMed Pharmaceuticals logo
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.89
Low: $0.89
High: $0.89

52 Week Range

Now: N/A

Volume

1,201 shs

Average Volume

768,904 shs

Market Capitalization

$34.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of OncoMed Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on OncoMed Pharmaceuticals in the last twelve months:
View the latest analyst ratings for OMED.

What is the current price target for OncoMed Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for OncoMed Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for OncoMed Pharmaceuticals in the next year.
View the latest price targets for OMED.

What is the current consensus analyst rating for OncoMed Pharmaceuticals?

OncoMed Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OMED.

What other companies compete with OncoMed Pharmaceuticals?

Other companies that are similar to OncoMed Pharmaceuticals include Magenta Therapeutics, Apexigen, Novan, Bionomics and Aptinyx. Learn More about companies similar to OncoMed Pharmaceuticals.

How do I contact OncoMed Pharmaceuticals' investor relations team?

OncoMed Pharmaceuticals' physical mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company's listed phone number is 650-995-8200 and its investor relations email address is [email protected] The official website for OncoMed Pharmaceuticals is www.oncomed.com. Learn More about contacing OncoMed Pharmaceuticals investor relations.